Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data
Shares of Biogen $BIIB and Ionis Pharmaceuticals $IONS both jumped early Monday morning after the two biotech partners announced another preliminary win in a late-stage study of nusinersen for spinal muscular atrophy.
The latest batch of good news — badly needed by both of these companies — centers on a positive readout for nusinersen (Spinraza) for late-onset SMA. The first round of promising results dropped three months ago for early-onset cases and Biogen says the FDA has already signaled that it plans to act early on its application to start selling the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
